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Abstract
Background & Aims. The health related quality of 
life (HR-QoL) construct was introduced as a requirement 
to assess the subjective health status. It is a multifaceted 
construct that has contributed to a better understanding of 
the patients’ adaptation to his condition. The Inﬂammatory
Bowel Disease Questionnaire (IBDQ), a widely used 
instrument to assess QoL among IBD patients, has already 
shown its validity and reliability. Our aim was to obtain an 
easier revised version of the (IBDQ-R) and to investigate 
its cross-cultural psychometric properties. Method. Carried 
out in a sample of outpatients recruited in a specialized 
University Clinic (n=76), this study began with the translation 
and linguistic validation of a self-report 32-item version of 
the questionnaire with a 7-point Likert type answering 
system. We assessed thereafter its reliability through internal 
consistencies and also looked into its discriminatory power. 
We also investigated its convergent validity with other health 
status - clinical assessment, SCDAI and CDAI-m - and 
well-being measures. Results. With a Cronbach’s alpha = 
0.92 for the global scale and a mean 0.82 for the subscales, 
internal consistencies proved adequate. On the other hand, 
discriminatory power was also signiﬁcant according to
the model. Moreover, the expected correlations between 
IBDQ and the clinical assessment, SCDAI, CDAI-m and 
perception of well-being support evidence of IBDQ-R’s 
convergent validity. Conclusion. This IBDQ revised version 
is a highly promising instrument to easily, yet feasibly and 
comprehensively, assess the quality of life in inﬂammatory
bowel disease; therefore its use in daily practice is worthy 
to be recommended.
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Introduction
At a certain point a generalized conviction arose that the 
morbidity indexes commonly used to assess the outcome of 
health interventions were relatively poor in respect to the 
information they made available. This is what led to look for 
other means to assess the health status, namely the subjective 
health status, including the Quality of Life (QoL). This 
term is designed to cover the aspects essentially connected 
with medical care and health related experiences. A more 
precise description is given by the term health related QoL 
(HR-QoL), thus cleaning its multidimensional content from 
the exclusion of aspects unrelated with the aims of medical 
intervention [1].
But despite the abundant literature on the subject, one 
has to admit that its penetration in daily practice is still 
timid [2]. Indeed, the clinical body has kept some distrust 
towards adopting HR-QoL in its daily practice, to quantify 
the outcomes of its interventions, variables referred to human 
characteristics, side by side with lab data or endoscopic 
ﬁndings. Nevertheless, particularly when dealing with
chronic conditions, one can assume as a primordial goal 
for the therapeutic intervention to somehow improve the 
patient’s QoL; and this should be, in a ﬁnal analysis, the
touchstone to evaluate more effectively the outcomes of 
such intervention. What happens instead, to this purpose, 
is that the activity indexes in use, i.e. for inﬂammatory
bowel disease (IBD), not only revealed  themselves as little 
sensitive, but even conﬂicting with the patient’s perception
of his/her own status [3]. While on the opposite, these 
QoL indexes, in terms of clinical assessment of the disease 
activity, have been proved strongly related with better well-
being and lesser use of health services [4].
In fact, in what concerns patients, more than the lab 
ﬁndings and physiologic reactions, the matter is about
symptomatic complains and functional ability, where these 
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complains, assumed as of affective nature, are usually 
dismissed. Therefore it is important to assess the functional 
ability of the patients. That is, to screen patients with 
special needs, namely due to psychosocial difﬁculties,
that these instruments may indicate or allow to localize. 
Simultaneously these allow to monitor clinical evolution, 
eventually suggesting alternative therapeutic approaches.
Nevertheless, although QoL, as compared to clinical 
assessment, is a better indicator of the health care consumption 
[4, 5], what happens is that this kind of information — be 
it by mistrust, inadequacy, or unavailability in the right 
moment - seldom is considered in decision making by health 
managers [6].
The simplest method of assessment consists in making 
a single question to the patient, who will integrate in his 
answer the various dimensions involved. However, herein 
also resides its hindrance; that is, evaluations of a single 
issue will not give us any information on the factors leading 
to this or that other answer.
On the generic instruments [7, 8], these are characterized 
by not taking into account speciﬁc aspects of the disease in
question. Where the speciﬁc ones are designed to assess
some states and worries inherent to the patients afﬂict by
a particular disease. That will be the case of an instrument 
aimed at Crohn’s Disease (CD), which will have to include 
issues related to intestinal functioning, abdominal pain, 
or of a sexual nature; where another one oriented towards 
rheumatoid arthritis may instead be interested in assessing 
hand strength and mobility. Advantages of this speciﬁcity
reside in the added sensitivity to the clinical status variations 
that may occur along the evolution [9], hence a direct 
usefulness in clinical trials, but also the fact that the sort of 
questions and explored areas are very similar to those usually 
used by physicians for regular clinical assessment.
Conceived around its use in clinical trials, the Inﬂammatory
Bowel Disease Questionnaire (IBDQ) [10-13] is a structured 
interview commonly used to assess HR-QoL. Translated into 
many different languages [14] - Dutch [15, 16], Portuguese 
[17-19], Spanish [20-22], Korean [23], UK English [24, 
25], Greek [26, 27], Swedish [28, 29], Norwegian [30], 
Japanese [31, 32], German [33-35], Chinese [36], Lebanese 
[37], Brazilian [38] - it has shown its reliability, validity and 
cross-cultural stability.
The purpose of this study was to get an easy-to-use 
Portuguese version of the 32-item IBDQ and to investigate 
its cross-cultural psychometric properties.
Methods
Participants
The subjects for this study were recruited among 
patients being treated in an IBD specialized Clinic at the 
Gastroenterology Unit of a local University Hospital. Upon 
the hospital’s Ethics Committee approval, and in accordance 
with the Helsinki Declaration, the study was conducted in a 
one year period, during which, on a weekly consultation, the 
patient with the ﬁrst appointment scheduled was successivelly
approached. All the 76 interviewed outpatients - 28 men and 
48 women - after being properly informed, agreed upon free 
willing participation; thus providing written consent. All of 
them had their IBD diagnosed and classiﬁed by endoscopic
and histological means according with ICD-10 [39].
Instruments
The study and its aims were introduced in a ﬁrst moment
of the interview. Then, following a structured form, socio-
demographic data was collected by means of the Graffar 
index [40], as well as some relevant elements from the 
personal, familial and medical history.
Medical characterization
Inclusion criteria went through clinical classiﬁcation after
the radiologic, endoscopic and/or histopathological elements 
which allowed characterizing the location and extension. 
These were further consolidated with other objective data 
available from the patient’s ﬁles.
Physician-reported global assessment
The accompanying specialized clinician was also asked 
to grade the disease activity on a ﬁve point scale, ranging
from remission, mild and moderate, up to severe and very 
severe.
Survey Crohn’s disease activity index (CDAI)
In order to characterize subgroups according to the 
disease activity, we also used the Survey CDAI [41], an index 
accurately placing patients into quartiles of disease severity 
equivalent to those produced by the CDAI [42].
Modiﬁed CDAI
Starting with the CDAI [42] another index has been 
put forth on a modiﬁed version (CDAI-m). In fact, except
the hematocrit, the other variables required to calculate 
CDAI were available or else could be inferred after proper 
coding.
Taking into account that, as compared to clinical 
indicators, one can not conclude on the superiority of the 
biological parameters [43], the hematocrit was put aside from 
the start. The data actually collected about liquid or very soft 
stools referred to the last 24 hours, and not to the required 7 
days of the week on a daily basis. Hence the deduction, to 
a certain extent, about the functional status along the last 7 
days, ascertained taking the available number of stools of 
the last 24 hours as the daily average. Once the variables 
were weighted, instead of being kept as absolute numbers, 
a pre-coded value was adopted in the context of the formula 
for stools/week. The coding process was as follows: 
[2 x (nr. of stools/week)] + [5 x (abdominal pain/week)] + [7 x 
(well-being/week)] + [20 x (extra-intestinal manifestations/week)] 
+ [30 x (taking lomotil or opiates for diarrhea)] + [10 x (abdominal 
mass (0, 2, 5))] + [weight loss]
Although not equivalent to the CDAI, the resulting 
variable is an acceptable index to be used, side by side with 
others also here considered.
Patient-reported global assessment
Perception of well-being was quantiﬁed as proposed in
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the Harvey-Bradshaw index [44], that is, the patient was 
asked, on a 0 to 4 scale — ranging from very well, good, 
fair, poor or very poor/terrible — how would he/she describe 
his general health status and well-being.
IBD questionnaire - revised (IBDQ-R)
Comprising 32 issues, besides a global score, the IBDQ 
covers bowel and systemic symptoms, as well as emotional 
status and social functioning. Well conceived, it has been 
repeatedly shown a psychometrically sound measure while 
replicable, stable and sensitive to variations among patients 
with IBD, outpatients as well as inpatients [10, 13-15, 24, 
30, 45, 46].
In its original form, each question is followed by the 
enunciation in full of each and every possible alternative 
answer; 7 in all, one after the other. What, besides making it 
quite large, turns out to be hardly understandable by patients 
with an average education level, who have to successively 
memorize all the different options until reaching a decision 
on the ﬁnal answer. This has been acknowledged from the
start [46], in terms of validating the self-administration 
form [47] or of putting forward a shorter version scored in 
a 7-point scale [48].
In this revised 32-item version we addressed these issues 
proceeding to an adaptation of a self-report Likert style 
questionnaire. To achieve answering consistency along the 
questionnaire, in order to have a single header for the 32 
items, we had to take into account the contents: afﬁrmatively,
or else negatively valued; and also the direct or reverse 
score of the respective item. This shortened it to two pages, 
important in the global context of the practicality of a time 
consuming evaluation requiring different instruments.
The questionnaire is administered to the patient with 
a brief explanation on the answering mode, mentioning 
that he/she should answer the questions thinking only in 
which extent those aspects have been present in the last 
two weeks.
Results
General characteristics
The ulcerative colitis (UC) subgroup consisted of 26 
patients - 14 men and 12 women, with a mean age of 44.42 
± 12.64 years and a mean disease duration of 9.67 ± 7.59 
years. Five patients with UC were asymptomatic, 6 had a 
mild disease activity, 7 had moderate activity, and 8 were 
in a more severe state.
The CD subgroup included 50 patients - 16 men and 
34 women – with a mean age of 34.76 ±12.41 years and a 
mean disease duration of 10.15 ± 8.01 years. Eight patients 
with CD were in remission, 15 had a mild activity, 17 had 
moderate activity and 10 had severe activity.
Besides patients with UC being older than those with CD 
(p = 0.002), there were no signiﬁcant differences between
the two subgroups  concerning the mean Graffar index. This 
was 15.51 ± 3.45/25 for the whole sample, with a statistical 
mode of 3/5 - corresponding to a socioeconomic class III in 
the Hollingshead index. There were no signiﬁcant differences
regarding the duration of the disease, but signiﬁcant regarding
the age of onset, which was younger for CD (24.80 ± 11.00) 
than for UC patients (34.77 ±12.79) (p = 0.001).
The IBD activity was at level 1 (quiescent) in 13 patients, 
at level 2 (mild) in 21 patients, at level 3 (moderate) in 24 
patients, and at level 4 (severe) in the other 18. The ratio 
between patients with asymptomatic/mild activity (UC = 
42.3%, CD = 46.0%) and those with severe symptoms (UC 
= 57.7%, CD = 54.0%) was not signiﬁcantly different.
Most of the patients were treated with 5-aminosalicylate 
- 90% of the CD patients and 92.3% of those with UC, as well 
as, according with the disease’s activity, with corticosteroids: 
48% of the CD patients and 26.92% of those with UC. It is 
noteworthy that 36% of the CD patients and 42% of those 
Table I. IBDQ-R - Portuguese version
Reliability of the scales
IBDQ-R
(N = 76)
Item-Total
Correlation
Rmult2 Cronbach’s 
α
If excluded
Global score α = 0.92
Bowel symptoms
 α= 0.84
BS-01 0.45 0.27 0.83
BS-05 0.39 0.35 0.84
BS-09 0.68 0.75 0.81
BS-13 0.79 0.82 0.80
BS-17 0.50 0.31 0.83
BS-20 0.62 0.48 0.82
BS-22 0.49 0.31 0.83
BS-24 0.65 0.49 0.81
BS-26 0.41 0.31 0.84
BS-29 0.38 0.35 0.84
Systemic 
symptoms
α= 0.77
SS-02 0.63 0.45 0.70
SS-06 0.56 0.36 0.72
SS-10 0.63 0.45 0.69
SS-14 0.45 0.22 0.76
SS-18 0.47 0.23 0.76
Emotional status
α= 0.87
ES-03 0.65 0.69 0.86
ES-07 0.32 0.39 0.88
ES-11 0.62 0.49 0.86
ES-15 0.70 0.50 0.85
ES-19 0.57 0.48 0.86
ES-21 0.62 0.56 0.86
ES-23 0.42 0.32 0.87
ES-25 0.74 0.62 0.85
ES-27 0.56 0.52 0.86
ES-30 0.69 0.64 0.86
ES-31 0.53 0.41 0.86
ES-32 0.42 0.36 0.87
Social 
functioning
α= 0.87
SF-04 0.59 0.39 0.78
SF-08 0.64 0.41 0.76
SF-12 0.63 0.42 0.77
SF-16 0.53 0.39 0.80
SF-28 0.64 0.45 0.77
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with UC also received psychopharmacological drugs, mainly 
patients with simultaneous prescription of corticoids.
Reliability (Table I)
Internal consistencies, evaluated by means of the 
Cronbach’s coefﬁcient alpha [49], were reasonably high: the
overall questionnaire equals 0.92 and the subscales a mean 
0.82. Multiple regressions item-scale - correlation between 
each item and the sum of all others in the scale - goes also 
in the same sense, leaving as marginal the contribution of 
item 7 for the emotional status.
The same consistency was found for CD and UC when 
item analysis was performed independently for both groups. 
Namely with a 0.97 Cronbach’s alpha for the global score 
and a mean 0.82 for the subscales, in  the case of CD; and 
in the case of UC, with a Cronbach’s alpha equal to 0.96 for 
the global score and a mean of 0.83 for the subscales.
Discriminatory ability (Table II)
To crudely assess its responsiveness, we tested the 
instrument’s  ability to discriminate patients according to 
disease activity as assessed by the SCDAI and categorizing 
them into quartiles. Then the lower quartile subgroup 
- clinical remission to mild activity - was compared with 
the higher quartile one — moderate to severe activity. 
We observed that the IBDQ-R global score, as well as 
its subscales’, was signiﬁcantly lower (p = 0.000) among
patients with a less controlled illness.
Construct convergent validity (Table III)
As it may be seen by Pearson r, IBDQ-R scores were also 
signiﬁcantly lower (i.e. poor QoL), the worst the health status
as assessed by other objective means: SCDAI (r = - 0.62; 
p = 0.000) and CDAI-m (r = - 0.62; p = 0.000). They were 
signiﬁcantly related, as expected, with a poor perception
of well-being (r = - 0.53; p = 0.000). The same signiﬁcant
relationships were reproducible both in CD and UC.
Discussion
In general terms, the here analyzed instrument to 
speciﬁcally assess QoL in IBD has content value: its
questions effectively represent the aspects meant to be 
explored. This refers to the scale construct validity, seeing 
that, built about a hypothesized model of health status, it 
was tested in patients previously characterized by their 
speciﬁcity, thus conﬁrming the model. But it also refers to
the concurrent validity, since the respective scores, although 
not fully overlapping, correlate with those in other previously 
used instruments that were also meant to assess some of 
the aspects involved in general well-being: patient report, 
physician global assessment, survey CDAI and modiﬁed
CDAI.
The item analysis revealed in turn that the instrument is 
rather homogeneous in its dimensions. In fact, the internal 
consistency as assessed by the Cronbach’s alpha, as well as 
by the item-total correlations, indicate just that. 
Based on our data one can discuss the scale’s sensitivity, 
since its discriminatory power allows us to conclude about 
its usefulness to record changes as the clinical condition 
changes. Nevertheless, although promising, its usefulness 
should be further explored in samples speciﬁcally collected
among in-patients, as well as out-patients, in order to 
deﬁnitely establish its behavior in relation to the ‘ceiling’and
‘ﬂoor’effects.And since this study adopted a cross-sectional
approach, further prospective research is also required in 
order to effectively establish its predictive power. 
Due to the particular type of target population under 
scrutiny, which refers to diseases relatively uncommon 
Table II. IBDQ-R - Portuguese version (n=76)
Discriminatory ability according to SCDAI
Lower 
Quartile
(N = 19)
Higher Quartile
(N = 19)
Student‘s 
t
p
IBDQ-R 
Global score
176.58 ± 34.11 118.42 ± 25.63 5.94 0.000
Bowel 
Symptoms
58.63 ± 10.51 40.00 ± 8.96 5.88 0.000
Systemic 
Symptoms
23.53 ± 6.96 15.37 ±  4.92 4.17 0.000
Emotional 
Status
65.32 ± 12.70 42.11 ±  9.32 6.42 0.000
Social 
Functioning
29.11 ±  6.93 20.95 ±  7.76 3.42 0.000
General well-
being
0.00 ±  0.00 2.00 ±  0.94 - 9.25 0.000
Clinical 
Assessment
0.21 ±  0.42 1.79 ±  1.03 - 6.18 0.000
SCDAI 29.84 ± 10.02 333.58 ± 77.74 - 16.89 0.000
Table III. IBDQ-R - Portuguese version (Pearson r correlations)
Convergent validity (N = 76)
Clinical assessment SCDAI CDAI-m General W-B
r p r p r p r p
IBDQ-R Total - 048 0.000 - 0.62 0.000 - 0.62 0.000 - 0.53 0.000
Bowel symptoms - 0.46 0.000 - 0.63 0.000 - 0.61 0.000 - 0.43 0.000
Systemic symptom - 0.50 0.000 - 0.55 0.000 - 0.57 0.000 - 0.51 0.000
Emotional status - 0.40 0.000 - 0.60 0.000 - 0.59 0.000 - 0.55 0.000
Social functioning - 0.41 0.000 - 0.38 0.001 - 0.40 0.000 - 0.38 0.001
SCDAI: Survey Crohn‘s activity index; CDAI-m: Crohn‘s activity index modiﬁed; W-B: well-being
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- IBD prevalence from US estimate around 89.6-103.0 per 
100,000 persons for CD and 146.6-164.9 per 100,000 person 
for UC - we had to prolong data collection in the ﬁeld for
a 1 - year long period. This was a limitation, since the size 
of the collected sample, although proven adequate for the 
analysis performed in this study, did not have enough power 
to allow us to further analyze the internal structure of the 
questionnaire by means of Factorial Analysis. Nevertheless, 
although open to further Conﬁrmatory Analyses, the
present ﬁgures, namely on internal consistencies, are rather
suggestive by themselves.
The IBDQ is a rather informative tool, comprising four 
factors, besides a global score on subjective health status: 
namely covering bowel and systemic symptoms, as well as 
the emotional status and social functioning. 
In conclusion, we consider that this IBDQ revised 
version is a feasible instrument that comprehensively 
assesses QOL among IBD patients. Given the fact that CD 
and UC are chronic debilitating diseases with an important 
adverse impact on patients’ lives, and bearing in mind that, 
together with a rather straightforward scoring system, its size 
- 32 issues in a single sheet (two pages) layout - and the fact 
that it can be self-administered, make the task of collecting 
data a very easy and fast one, the use of IBDQ revised version 
should be recommended for research - epidemiological, 
clinical trials, etc. - as well as for daily practice. 
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